
Via @GreenJournal: Researchers have found Class IV evidence of an association between rituximab and a lower hazard to relapse in patients with autoimmune encephalitis: bit.ly/3QcevkB #NeuroTwitter @AANMember

Neuroimmunologist, clinician scientist investigating the immunobiology of autoimmune encephalitis

Via @GreenJournal: Researchers have found Class IV evidence of an association between rituximab and a lower hazard to relapse in patients with autoimmune encephalitis: bit.ly/3QcevkB #NeuroTwitter @AANMember

In NMDA receptor #encephalitis, patients with persistent CSF NMDAR-Abs at 12 months were more likely to have subsequent relapses and a poor long-term outcome
Stop scrolling, here is our new article regarding Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis pubmed.ncbi.nlm.nih.gov/3714… @lundahl1 @Vogrig_Alberto @maccuve @GnclvsDavid #autoimmune #encephalitis #antinmdar

Don’t miss this excellent updated review: “Autoimmune encephalitis: recent clinical and biological advances” @ANG_Oxford link.springer.com/article/10…

Cytotoxic T cells and plasma cells dominate early in temporal lobe epilepsy with GAD antibodies. New scientific commentary by Franziska Thaler & Edgar Meinl https://t.co/HKTdMHPmUL

Steinke et al. develop and validate a construct that neutralizes autoantibodies from patients with NMDAR encephalitis, and prevents receptor internalization and memory deficits in a mouse model. https://t.co/q7ODQHPpxx

Thanks @AAN @GreenJournal N2 for publishing our experience using prolonged corticosteroids for anti-LGI1 encephalitis. Examining the impact of acute immunotherapy regimen on need for maintenance immunotherapy may help optimize our treatment approach. nn.neurology.org/content/10/…

Congratulations to @LabMader on their new publication! 🥳It was a pleasure to contribute. Take a look at the pathomechanisms of MOG-antibody-associated disease: pnas.org/doi/10.1073/pnas.23…

Happy to share our new manuscript. Many thanks to all co-authors for this great collaboration! @kathieisenhut, @edubeltran_lab, @LabMader, @Ker_Lab, @LabMeinl, @INIM_Munich https://t.co/nOoeHHBQsm

In a large cohort of patients with anti-IgLON5 disease, Grüter et al. reveal early inflammatory CSF changes, and association of HLA-DRB1*10:01 with higher autoantibody titre, consistent with a primary autoimmune nature of the disease. https://t.co/GoOhcYQM1R

Study data support the hypothesis that the accumulation of GAD65-specific B cells and plasma cells in the CSF is an important feature of early disease stages of GAD65-Ab spectrum disorders, such as stiff-person syndrome and cerebellar ataxia. Learn more: https://t.co/Gqoymei7pV

What happened to #neurological #autoantibody detection rates around the pandemic? We compared 2019 Vs 2020, across the 5 commonest cell surface Abs, and only saw a fall in LGI1 rates. The drop was marked around March-June - the time of the UK lockdown. jamanetwork.com/journals/jam…

Check out our new manuscript. Many thanks for this great collaboration: @Samanth68485267, Eva Oswald, Hoi Kiu Wong, @AtayVural, Vuslat Yilmaz, Erdem Tüzün, Recai Türkoğlu, Tobias Straub, Ingrid Meinl, @ThalerLab, Tania Kümpfel @LabMeinl,@LabMader
Happy to contribute to this exciting study that uncovers a novel mechanism of effect for ocrelizumab on the BAFF-APRIL system. Cheers to my colleagues Simone Mader and Edgar Meinl and other collaborators 🥂 nn.neurology.org/content/10/… @LabMeinl @LabMader

Tröscher et al. show that in patients with GAD65 antibody-associated temporal lobe epilepsy, cytotoxic T cells attack and kill neurons and are responsible for the early neuronal loss. https://t.co/9buT7VWUdd